Primecap Management Co. CA Decreases Stock Position in Axon Enterprise, Inc $AXON

Primecap Management Co. CA trimmed its position in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 25.0% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 13,200 shares of the biotechnology company’s stock after selling 4,400 shares during the quarter. Primecap Management Co. CA’s holdings in Axon Enterprise were worth $9,473,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in AXON. Intech Investment Management LLC lifted its holdings in shares of Axon Enterprise by 420.5% in the 3rd quarter. Intech Investment Management LLC now owns 67,649 shares of the biotechnology company’s stock worth $48,548,000 after acquiring an additional 54,652 shares during the last quarter. RWA Wealth Partners LLC purchased a new stake in Axon Enterprise in the 3rd quarter worth about $214,000. Thoroughbred Financial Services LLC bought a new stake in Axon Enterprise in the third quarter worth about $1,469,000. First Heartland Consultants Inc. boosted its position in shares of Axon Enterprise by 29.9% during the third quarter. First Heartland Consultants Inc. now owns 864 shares of the biotechnology company’s stock valued at $620,000 after buying an additional 199 shares during the period. Finally, Mufg Securities Americas Inc. grew its stake in shares of Axon Enterprise by 29.2% during the third quarter. Mufg Securities Americas Inc. now owns 2,117 shares of the biotechnology company’s stock valued at $1,519,000 after buying an additional 478 shares during the last quarter. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Insider Transactions at Axon Enterprise

In other Axon Enterprise news, Director Jeri Williams sold 100 shares of the company’s stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $550.63, for a total transaction of $55,063.00. Following the completion of the sale, the director owned 1,316 shares in the company, valued at $724,629.08. This represents a 7.06% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Brittany Bagley sold 2,000 shares of the stock in a transaction on Thursday, December 11th. The shares were sold at an average price of $580.00, for a total value of $1,160,000.00. Following the sale, the chief financial officer directly owned 103,501 shares in the company, valued at $60,030,580. This trade represents a 1.90% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 58,040 shares of company stock worth $32,251,738. Insiders own 4.40% of the company’s stock.

Key Axon Enterprise News

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Q4 beat and bullish bookings — Axon reported a double beat (EPS and revenue), ~39% revenue growth and a material increase in future contracted bookings with raised multi‑year sales targets, which triggered the stock rally. Read More.
• Positive Sentiment: AI narrative driving subscription demand — Coverage highlights that Axon’s AI features (body‑camera analytics, Draft One report drafting, evidence management) are accelerating software adoption and upsells, supporting revenue visibility beyond hardware. Read More.
• Neutral Sentiment: Analysts recalibrating models — Several firms trimmed price targets after the print (Piper Sandler, others); many maintained buy/overweight stances, so these moves reflect model updates and volatility rather than a wholesale negative verdict. Read More.
• Neutral Sentiment: Short‑interest data flagged as anomalous — Recent short‑interest reports show zero/NaN figures (likely a reporting anomaly); nothing actionable from that data point for now.
• Negative Sentiment: Some analysts flag downside risk — Morgan Stanley and UBS issued more cautious outlooks/pessimistic scenarios that could cap upside if execution or margins slip. Read More. | Read More.
• Negative Sentiment: Profitability and margin recovery remain a watch item — Commentators note fast revenue growth but slower profit improvement and the need for FCF conversion; sustained margin progress is required to justify high multiples. Read More.
• Negative Sentiment: Insider sale disclosed — CEO Patrick Smith sold 10,000 shares (~$5.0M) on Feb. 25; small relative to his holdings but notable to traders monitoring insider activity. Read More.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on AXON. UBS Group decreased their price target on Axon Enterprise from $610.00 to $570.00 and set a “neutral” rating for the company in a research note on Wednesday. Needham & Company LLC reduced their target price on Axon Enterprise from $870.00 to $600.00 and set a “buy” rating on the stock in a research note on Friday, February 20th. Barclays decreased their target price on Axon Enterprise from $702.00 to $682.00 and set an “overweight” rating for the company in a research report on Wednesday. Robert W. Baird set a $800.00 price target on shares of Axon Enterprise in a report on Wednesday. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Axon Enterprise in a report on Monday, December 29th. Sixteen analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $762.93.

Axon Enterprise Stock Performance

Shares of Axon Enterprise stock opened at $542.40 on Friday. The firm has a market cap of $43.61 billion, a P/E ratio of 356.84, a P/E/G ratio of 16.57 and a beta of 1.48. The company has a current ratio of 2.53, a quick ratio of 2.89 and a debt-to-equity ratio of 0.53. Axon Enterprise, Inc has a 12 month low of $396.41 and a 12 month high of $885.91. The stock’s fifty day moving average price is $537.92 and its 200-day moving average price is $625.54.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $2.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.60 by $0.55. The company had revenue of $796.72 million during the quarter, compared to analyst estimates of $755.29 million. Axon Enterprise had a net margin of 4.48% and a return on equity of 2.82%. The firm’s revenue for the quarter was up 38.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.08 earnings per share. On average, equities research analysts expect that Axon Enterprise, Inc will post 5.8 earnings per share for the current fiscal year.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.